Search Clinical Trials in the European Union

Duration
6-10 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
461-480 of 604 trials

Seizures in Developmental and Epileptic Encephalopathies: LP352 Study

We are investigating whether LP352 can help reduce seizures in children and adults with developmental and epileptic encephalopathies. This study compares the medication to a placebo to assess its effectiveness and safety.

Developmental and Epileptic EncephalopathiesConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Kidney Cancer: New Combination Therapies

We are studying new treatment combinations for people with recurrent kidney cancer after anti-PD-(L)1 therapy. The goal is to evaluate their safety and effectiveness in improving patient responses.

Clear Cell Renal Cell Carcinoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Luspatercept for Anemia in Lower-Risk MDS Patients

We are studying whether Luspatercept can improve anemia in patients with lower-risk myelodysplastic syndromes who do not require blood transfusions. The trial will also assess its impact on quality of life and safety.

Myelodysplastic Syndromes (MDS)3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematology

Liver Cancer: Tislelizumab Immunotherapy Study

We are testing a new immunotherapy for patients with liver cancer and moderate liver function. The study aims to see if it can improve treatment outcomes and quality of life.

Hepatocellular Carcinoma (HCC)>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHepatologyOncology

Chronic Hypertension in Pregnancy: Aspirin Study

We are investigating whether low-dose aspirin can help prevent serious complications in pregnant women with chronic hypertension. This includes risks like preeclampsia and preterm delivery.

Pregnancy-Related Hypertension and Pre-Eclampsia6-12 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteGynecology and ObstetricsInternal Medicine

Friedreich Ataxia: Vatiquinone Safety Study

We are studying the long-term safety of vatiquinone in patients with Friedreich Ataxia who have previously used this medication. We aim to see how it affects their symptoms over time.

Friedreich's Ataxia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurology

Clenbuterol for Spinal and Bulbar Muscular Atrophy (SBMA)

We are studying whether clenbuterol can help patients with SBMA manage their symptoms. We will also look at how well patients tolerate the treatment over time.

Spinal and Bulbar Muscular Atrophy6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesInternal MedicineNeurology

Clofarabine for Advanced Urothelial Carcinoma

We are studying the safety and effectiveness of Clofarabine in patients with locally advanced or metastatic urothelial carcinoma. The trial aims to find the highest dose that can be tolerated while assessing how well the treatment works.

Bladder Cancer3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Diabetic Cardiovascular Autonomic Neuropathy: The FibroCAN Study

We are investigating whether finerenone can help improve heart function and reduce nerve damage in people with type 2 diabetes and early-stage cardiovascular autonomic neuropathy. This study compares the treatment to a placebo to assess its effects.

Diabetic Cardiovascular Autonomic Neuropathy1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementCardiologyEndocrinologyNeurology

Activated T-Cells for Graft vs Host Disease After Stem Cell Transplant

We are testing a new treatment using activated regulatory T-cells in patients shortly after stem cell transplantation. The aim is to see if it can safely reduce the risk and severity of acute graft vs host disease.

LeukaemiaAcute graft versus host disease1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Stroke Care: HOPE Study on Blood Pressure Management

We are comparing standard blood pressure management to a personalized approach after mechanical thrombectomy for acute ischemic stroke patients. The goal is to see which method better supports recovery and brain health.

Acute Ischemic Stroke>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Cardiovascular Health in Type 2 Diabetes: COLCOT-T2D Study

We are studying whether colchicine and non-enteric coated aspirin can improve heart health in high-risk adults with type 2 diabetes. The goal is to see if these treatments can reduce serious heart-related events.

Unspecified Cardiovascular DiseaseConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteCardiologyEndocrinology

Maridebart Cafraglutide for Heart Failure and Obesity

We are studying whether maridebart cafraglutide can improve heart failure symptoms and reduce hospital visits for people with heart failure and obesity. This trial compares the new treatment to a placebo alongside standard care.

Heart FailureConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Buspirone for Weak Esophageal Motility

We are studying whether buspirone can improve swallowing and esophageal function in patients with poor motility. This trial compares the effects of buspirone to a placebo on symptoms and esophageal pressure measurements.

Ineffective Motility or Absent Peristalsis≤3 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesPartially RemoteGastroenterology

Multiple Sclerosis: Masitinib Treatment Study

We are investigating whether the oral medication masitinib is effective and safe for people with primary or secondary progressive multiple sclerosis without relapses. This study compares masitinib to a placebo to evaluate its impact on various symptoms and overall health.

Multiple Sclerosis1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteNeurology

Generalized Anxiety Disorder: ITI-1284 Treatment Study

We are evaluating the safety and effectiveness of a new medication, ITI-1284, for people with Generalized Anxiety Disorder who haven't found relief with current treatments. This study compares ITI-1284 to a placebo to see how well it works.

Generalized Anxiety Disorder≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPsychiatry

Granulomatosis with Polyangiitis: New Salvage Therapies

We are testing different treatment combinations for patients who haven't responded to standard care for granulomatosis with polyangiitis. The goal is to find the most effective way to help induce remission and improve overall health.

Granulomatosis with Polyangiitis (GPA)1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Eosinophilic Esophagitis: EP 104GI Treatment Study

We are testing a new treatment called EP 104GI for adults with eosinophilic esophagitis. The study aims to evaluate its safety and effectiveness in reducing symptoms and improving esophageal health.

Eosinophilic Esophagitis1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesAllergologyGastroenterology

MMRd Uterine Cancer: Pembrolizumab Treatment Study

We are investigating whether pembrolizumab can effectively treat MMRd uterine cancer before surgery. The study will assess how well it works and its safety for patients.

Endometrial Cancer1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGynecology and ObstetricsOncology

Multiple Sclerosis: IMU-838 Treatment Study

We are investigating the effects of a new medication, IMU-838, on disease activity in people with relapsing-remitting multiple sclerosis. This study aims to understand how well it works and how safe it is compared to a placebo.

Relapsing-Remitting Multiple Sclerosis3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology